On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on PRs and Gain Exclusive Benefits with NNW Prime! Click to View Details

Moleculin Biotech, Inc. (NASDAQ: MBRX) Starts Presentation at 30th Annual ROTH Conference

Moleculin Biotech (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. The company’s lead product candidate is Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin also has WP1066 … Continue reading “Moleculin Biotech, Inc. (NASDAQ: MBRX) Starts Presentation at 30th Annual ROTH Conference”

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Closes $9M Registered Direct Offering

Clinical stage pharmaceutical company Moleculin Biotech (NASDAQ: MBRX) has closed its offering of 4.29 million registered shares of common stock at a purchase price of $2.10 per share. Concurrently in a private placement, for each share of common stock purchased by an investor, the investor will receive an unregistered warrant to purchase 0.5 of a … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Closes $9M Registered Direct Offering”

Moleculin Biotech, Inc., (NASDAQ: MBRX) Starts Presentation at LD Micro Main Event

Moleculin Biotech (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on development of anti-cancer drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. The company’s lead product candidate is Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin also has two … Continue reading “Moleculin Biotech, Inc., (NASDAQ: MBRX) Starts Presentation at LD Micro Main Event”

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Files Annamycin IND with FDA for Acute Myeloid Leukemia

Shares of Moleculin Biotech (NASDAQ: MBRX) are trading 7% higher this morning following the company’s news that it has filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) to study Annamycin in the treatment of relapsed or refractory acute myeloid leukemia (AML). The company expects the FDA will allow the IND to … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Files Annamycin IND with FDA for Acute Myeloid Leukemia”

NetworkNewsBreaks – Moleculin Biotech, Inc.’s (NASDAQ: MBRX) CEO Shares Opinion on Recent FDA Drug Approvals for Acute Myeloid Leukemia

Shares of Moleculin Biotech (NASDAQ: MBRX) are up 9% mid-day following the company’s comments regarding the recent FDA approvals for new drugs for the treatment of acute myeloid leukemia (AML). The company’s drug candidate, Annamycin, is currently being evaluated for the treatment of relapsed or refractory AML. “While these new drugs make valuable incremental improvements … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc.’s (NASDAQ: MBRX) CEO Shares Opinion on Recent FDA Drug Approvals for Acute Myeloid Leukemia”

Moleculin Biotech (NASDAQ: MBRX) to Begin Preparing Clinical Testing Sites for Leukemia Treatment

NASDAQ Biotechnology Index up and climbing Developing new treatment for acute myeloid leukemia (AML) Lead candidate, Annamycin, now at phase II Since a rising sea lifts all boats, it’s decidedly good news for Moleculin Biotech, Inc. (NASDAQ: MBRX) that the NASDAQ Biotechnology Index (NBI) is enjoying a spring tide. The index has offered a year-to-date … Continue reading “Moleculin Biotech (NASDAQ: MBRX) to Begin Preparing Clinical Testing Sites for Leukemia Treatment”

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Selects Bioscience SA as Polish CRO

Shares of Moleculin Biotech (NASDAQ: MBRX) rose 7% this morning on news that the company has selected Bioscience SA, a Polish contract research organization (CRO), to begin identifying and preparing clinical testing sites in Poland for Annamycin. The company’s drug candidate, Annamycin, is being evaluated for the treatment of relapsed or refractory acute myeloid leukemia … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Selects Bioscience SA as Polish CRO”

Moleculin Biotech, Inc. (NASDAQ: MBRX) is “One to Watch”

Oncology pipeline features significant safety/efficacy advantages Lead candidate poised for FDA acceleration due to significant unmet need in AML Broad-spectrum applicability of WP1066 & WP1122 portfolios of molecules For preclinical oncology biopharma Moleculin Biotech, Inc. (NASDAQ: MBRX), the quest to deliver potentially revolutionary anti-cancer drugs to the market is enkindled by a close association with … Continue reading “Moleculin Biotech, Inc. (NASDAQ: MBRX) is “One to Watch””

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Names Lead European Principal Investigator in Anticipated Annamycin Clinical Trial

Shares of Moleculin Biotech (NASDAQ: MBRX) are up 11% after the company named Dr. Lidia Gil of Poznan University of Medical Sciences in Poznan, Poland, as the lead European Principal Investigator for the upcoming planned phase I/II clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML). The trial will … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Names Lead European Principal Investigator in Anticipated Annamycin Clinical Trial”

NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Reports Discovery of Metabolic Inhibitor with Potential to Treat Pancreatic Cancer; Shares Rise

Shares of Moleculin Biotech (NASDAQ: MBRX) are up more than 30% after the company said that WP1234, a metabolic inhibitor, is a positive drug candidate to be studied for the potential to treat pancreatic cancer. Pancreatic cancer is still considered mostly untreatable, so any improvement in treating this disease could symbolize a significant clinical benefit. … Continue reading “NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Reports Discovery of Metabolic Inhibitor with Potential to Treat Pancreatic Cancer; Shares Rise”

Contact us: 212.418.1217